|
|
|
|
Chem Asian J 2010,Apr,01;5(4):941-5; (PMID: 20235270)
[...]This type of reaction can also be applied to the preparation of the keto esters during the synthesis of seratrodast, which is an antiasthmatic and eicosanoid antagonist.
|
|
|
J Pharmacol Sci 2009,Dec,01;111(4):372-80; (PMID: 19942801)
[...]-induced vasoconstriction in young preparations and significantly attenuated vasoconstriction in adult preparations. Indomethacin, seratrodast, or tempol but not catalase significantly reduced methoxamine-induced vasoconstriction in adult preparations with [...]
|
|
|
Biol Pharm Bull 2008,Dec,01;31(12):2260-4; (PMID: 19043210)
[...], and evaluated the effects of commonly used and effective antiasthmatic drugs, i.e. ketotifen (antihistamine), pranlukast (anti-leukotriene C(4)/D(4)/E(4) (LT)), seratrodast (anti-thromboxane A(2) (TXA(2))), salbutamol (beta2-agonist), and prednisolone (steroid). The rat IAR model exhibited an optimal rapid airway response, and [...]
|
|
|
J Pharm Biomed Anal 2008,Sep,10;48(1):78-84; (PMID: 18562149)
Photodegradation of seratrodast ([+/-]-7-(3,5,6-trimethyl-1,4-benzoquinone-2-yl)-7-phenyl-heptanoic acid, SD), a p-benzoquinone anti-asthmatic drug, has been investigated in different solutions. HPLC analysis showed that SD was degradated under UV irradiation at 254 nm to afford three major products (SD1, SD2 and SD3) in [...]
|
|
|
Br J Pharmacol 2008,May,01;154(1):32-40; (PMID: 18332859) [FULL TEXT AVAILABLE]
[...]CGRP, isoprenaline, SNP and 8-Br-cGMP, but not BAY41-2272. Indomethacin (cyclooxygenase inhibitor) and seratrodast (thromboxane A(2) receptor antagonist), but not phosphoramidon (endothelin-1-converting enzyme inhibitor) or BQ-123 (selective endothelin type A receptor antagonists), significantly augmented vasodilator responses to PNS and [...]
|
|
|
Br J Pharmacol 2008,Feb,01;153(4):669-75; (PMID: 18037905) [FULL TEXT AVAILABLE]
[...] effects of KP-496 (1%) were comparable to those of montelukast (a CysLT(1) antagonist, p.o., 0.3 mg kg(-1)) or seratrodast (a TP antagonist, p.o., 3 mg kg(-1)). KP-496 (1%) and oral co-administration of montelukast (10 mg kg(-1)) and [...]
|
|
|
Int Immunopharmacol 2007,Nov,01;7(11):1483-7; (PMID: 17761352)
[...]For the above purpose, we studied the effects of pranlukast and zafirlukast (cysteinyl leukotriene (cys-LT) receptor antagonists), seratrodast and ramatroban (thromboxane A(2) (TXA(2)) receptor antagonists) on nasal congestion and sneezing[...]
|
|
|
Allergol Int 2006,Dec,01;55(4):403-10; (PMID: 17130683)
[...] but was more potent than that of montelukast. The TXA(2) antagonistic activity of KP-496 was comparable to that of seratrodast. KP-496 and seratrodast also inhibited the prostaglandin (PG) D(2)- and PGF(2alpha)-induced contractions of the isolated [...]
|
|
|
Eur J Pharmacol 2006,Aug,21;544(1-3):111-7; (PMID: 16844110)
[...]A thromboxane A2 (TXA2) synthase inhibitor, ozagrel, and prostanoid TP receptor antagonists, seratrodast and ONO-3708, also inhibited the neuropeptide Y-induced potentiation. In the endothelium-denuded arteries, a [...]
|
|
|
Prostaglandins Other Lipid Mediat 2004,Oct,01;74(1-4):125-37; (PMID: 15560121)
[...]Sensitized animals were repeatedly challenged by pollen inhalation once every week. Combined treatment with pranlukast (a CysLT antagonist) and seratrodast (a TXA2 antagonist) inhibited late phase nasal blockage, but the magnitude of inhibition (approximately 50%) was equal to those of the respective single treatments, suggesting that CysLTs produced late after challenge induces [...]
|
 1 2 3 4 5 6 
|
|
